Tolerability of spironolactone in patients with chronic heart failure - a cautionary message

被引:22
作者
Witham, MD [1 ]
Gillespie, ND
Struthers, AD
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Sect Ageing & Hlth, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland
关键词
aged; congestive; heart failure; spironolactone;
D O I
10.1111/j.1365-2125.2004.02187.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To assess how well heart failure patients tolerate spironolactone in routine clinical practice. Design Retrospective analysis of 226 patients attending a specialist heart failure clinic. Results One hundred and thirty of 226 (57.5%) patients tried spironolactone at least once. Forty-four of 130 (33.8%) discontinued spironolactone due to side-effects after a mean of 11.1 months; 59/141 (41.8%) trials of spironolactone resulted in at least one side-effect; therapy was stopped in 30/141 (21.3%) trials due to raised potassium or creatinine. Significant risk factors for raised potassium/creatinine were age and baseline potassium level. Conclusions Potentially serious side-effects are common despite appropriate use of spironolactone.
引用
收藏
页码:554 / 557
页数:4
相关论文
共 9 条
[1]   The safety of spironolactone treatment in patients with heart failure [J].
Anton, C ;
Cox, AR ;
Watson, RDS ;
Ferner, RE .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (04) :285-287
[2]  
Berry C, 2001, Heart, V85, pE8, DOI 10.1136/heart.85.4.e8
[3]   Complications of inappropriate use of spiroholactone in heart failure: When an old medicine spirals out of new guidelines [J].
Bozkurt, B ;
Agoston, I ;
Knowlton, AA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (02) :211-214
[4]   Diagnosis and management of heart failure in the elderly [J].
King, D .
POSTGRADUATE MEDICAL JOURNAL, 1996, 72 (852) :577-580
[5]   Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas [J].
Lien, CTC ;
Gillespie, ND ;
Struthers, AD ;
McMurdo, MET .
EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (01) :91-98
[6]   The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].
Pitt, B ;
Zannad, F ;
Remme, WJ ;
Cody, R ;
Castaigne, A ;
Perez, A ;
Palensky, J ;
Wittes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717
[7]   Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases [J].
Schepkens, H ;
Vanholder, R ;
Billiouw, JM ;
Lameire, N .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (06) :438-441
[8]   Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study [J].
Svensson, M ;
Gustafsson, F ;
Galatius, S ;
Hildebrandt, PR ;
Atar, D .
BRITISH MEDICAL JOURNAL, 2003, 327 (7424) :1141-1142
[9]   Lesson of the week -: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers:: analysis of 44 cases [J].
Wrenger, E ;
Müller, R ;
Moesenthin, M ;
Welte, T ;
Frölich, JC ;
Neumann, KH .
BRITISH MEDICAL JOURNAL, 2003, 327 (7407) :147-149